Liver toxicity is the main safety reason for drug attrition in clinical trials, causing 1 in every 13 drugs to fail. We have developed a novel, human liver model in a dish called hello which accurately predicts the toxicity of drugs.

the HUB provides access to a unique and robust platform that links patient-specific genetic and phenotypic information to preclinical and clinical drug-responsiveness.

Hy2Care develops a so called “injectable plaster” to repair the cartilage surface.

At Hybridize, we have developed a cost-effective proprietary therapeutic compound that can be intravenously administered to protect the kidney from BKV-mediated damage while maintaining full immunosuppression.

Basal cell carcinoma is the most diagnosed cancer worldwide. IMcoMET is developing a novel treatment method that will lead to removal of lesions with only minor side effects.

Injectable bone filler with drug release function for treatment of bone infections (INBORN)

Incircular Biotechnologies uses its unique patented INCYPRO technology to stabilize G protein-coupled receptors (GPCRs) for reliable applications in drug discovery. This will enable the development of drug candidates for currently non-targeted GPCRs.

Liquid biopsy platform for purification and collection of intact CTCs directly from blood

An infusion set that guarantees stability and immediacy of drug administration for preterm babies

Our in-silico platform can simulate stent-retriever-based thrombectomy in various patient-specific scenarios of varying vascular anatomy and clot characteristics. This allows the medical device industries to evaluate the performance of their novel devices before pre-clinical testing.